Ozempic/Wegovy (semaglutide) , Novo Nordisks GLP-1 receptor agonist, has patent protection running through the early 2030s in most markets, though the precise timeline is subject to ongoing litigation from generic and biosimilar challengers who are already preparing entry strategies [39]
Because tirzepatide activates both GIP and GLP-1 receptor systems, it provides a useful research tool for examining receptor cross-talk, signaling bias, and coordinated regulation of metabolic pathways in controlled experimental environments
One pharmacokinetic detail worth noting: Dihexa has an unusually long half-life of approximately 12 days
Your electrolytes (sodium, potassium, magnesium) become destabilized when dehydration combines with reduced eating and alcohol consumption
According to research and before and after stories , most people notice changes within the first few weeks to months of taking semaglutide
You're not imagining the exhaustion